EGFR and cancer: Signaling through the Epidermal Growth Factor Receptor (EGFR) pathway is a common event in cancer development [1], with activating mutations in KRAS, NRAS and BRAF occurring in approximately 50% of colorectal cancer (CRC) patients [2].